CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
ocrelizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03344094
NCT03344094N/ACompleted
CompareCT.gov

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

University of Chicago·observational·Posted Nov 17, 2017·Updated Feb 21, 2025

In Brief

An observational study evaluating ocrelizumab for Multiple Sclerosis and Immune System Diseases. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Immune System Diseases
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 17, 2017
Enrollment StartFeb 23, 2018
Primary CompletionApr 10, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.6 years ago

Interventions

ocrelizumabdrug

FDA-approved MS drugs